Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial

Yan Lou,Lin Liu,Hangping Yao,Xingjiang Hu,Junwei Su,Kaijin Xu,Rui Luo, Xi Yang,Lingjuan He,Xiaoyang Lu,Qingwei Zhao,Tingbo Liang,Yunqing Qiu

medRxiv（2021）

引用 146|浏览2

暂无评分

摘要

•An exploratory randomized, controlled trial of baloxavir marboxil and favipiravir in COVID-19 patients were conducted.•The free drug concentrations of baloxavir acid and favipiravir are generally lower than their respective EC50 values.•Add-on either baloxavir or favipiravir to the current standard treatment resulted in no additional antiviral benefit.

查看译文

关键词

COVID-19, baloxavir marboxil, favipiravir, pharmacokinetics, the half-maximal effective concentration (EC50)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要